Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill combo aims to slow stomach cancer after first treatment fails

NCT ID NCT07552402

Not yet recruiting Disease control Sponsor: Harbin Medical University Source: ClinicalTrials.gov ↗

First seen May 12, 2026 · Last updated May 12, 2026

Summary

This study tests whether a combination of an oral chemotherapy (paclitaxel solution) and a targeted drug (fruquintinib) can help control advanced stomach or gastroesophageal junction cancer after the first treatment stops working. About 150 adults whose cancer has worsened after initial therapy will be randomly assigned to receive either this new combination or a standard treatment chosen by their doctor. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA